Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trialLucia Del Mastro, Francesco Cognetti, Sabino De Placido et al.|The Lancet|2015Cited by 201
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid TumorsThierry André, Susana Banerjee, A. Antón Torres et al.|JAMA Network Open|2023Cited by 120
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET StudyAna Oaknin, Anna V. Tinker, Bhavana Pothuri et al.|Clinical Cancer Research|2023Cited by 80
Expression of insulin-like growth factor (IGF)-II and IGF-I receptor during proliferation and differentiation of CaCo-2 human colon carcinoma cells.Raffaele Zarrilli, Angela M. Acquaviva, Sandro Pignata et al.|PubMed|1994Cited by 50
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trialLucia Del Mastro, A Parisi, Francesca Poggio et al.|The Lancet Oncology|2022Cited by 50